Individuals with atrial fibrillation (Afib), or irregular heart rhythm, are at increased risk of stroke, chronic kidney ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

Use of SGLT-2 inhibitor therapy at admission was associated with a 32% reduced risk for acute kidney injury (AKI) in hospitalised patients, and this benefit was maintained when therapy was continued ...

A 112,000-patient study links SGLT2 inhibitors to lower dementia risk in people with psychiatric disorders. Read what it could mean.

A BMJ guideline put patient risk into the equation for assessing the suitability of SGLT-2 inhibitors and GLP-1 receptor agonist drugs for type 2 diabetes. Their use in type 2 diabetes was only ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

The U.S. SGLT2 Inhibitors Market is projected to grow from USD 5.49 Billion in 2025 to USD 11.06 Billion by 2035, while ...

After one year, people taking a GLP-1 drug had better outcomes than those taking an SGLT-2 drug. Specifically, they were 36% less likely to die from any cause, 12% less likely to be hospitalized, 22% ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...